Abbott, Google Health to develop AI glucose monitoring tools
Partnership combines Abbott’s continuous glucose monitoring tech with Google’s AI to enhance diabetes management analytics.
Abbott Laboratories and Google Health announced a collaboration to develop advanced artificial intelligence tools for glucose monitoring, aimed at improving diabetes care through data-driven insights.
Under the partnership, Abbott’s continuous glucose monitoring (CGM) systems will integrate with Google’s AI and machine learning capabilities to analyze glucose data more effectively. The initiative seeks to deliver personalized recommendations for patients and healthcare providers, potentially enhancing treatment decisions and outcomes.
Abbott’s CGM devices, including the FreeStyle Libre system, track glucose levels in real time without fingersticks, providing users with continuous data. Google Health will contribute its expertise in AI-driven health analytics to process this data, identifying patterns and trends that may inform clinical interventions.
The companies did not disclose financial terms or a timeline for commercialization. The collaboration underscores a broader trend in healthcare toward leveraging AI to refine chronic disease management, particularly in diabetes, where precise glucose control is critical.
Abbott, a leader in diabetes care technology, has expanded its CGM portfolio in recent years, while Google Health has increasingly focused on AI applications in health diagnostics and patient monitoring.
Helena covers corporate news for listed and private companies across Europe, from strategy shifts to leadership changes, with an eye for what a story signals about the broader market.
More from Helena Vásquez →
